share_log

Short Interest in HUTCHMED (China) Limited (NASDAQ:HCM) Drops By 18.9%

Short Interest in HUTCHMED (China) Limited (NASDAQ:HCM) Drops By 18.9%

空头股数在和黄医药(中国)有限公司(纳斯达克：HCM)下跌18.9%
kopsource ·  2022/10/02 22:52

HUTCHMED (China) Limited (NASDAQ:HCM – Get Rating) saw a significant decrease in short interest in the month of September. As of September 15th, there was short interest totalling 1,760,000 shares, a decrease of 18.9% from the August 31st total of 2,170,000 shares. Based on an average daily volume of 350,900 shares, the short-interest ratio is presently 5.0 days.

和黄医药(中国)有限公司(纳斯达克：HCM-GET评级)在9月份看到空头股数的销售额大幅下降。截至9月15日，空头股数共有176万股，比8月31日的217万股减少了18.9%。以日均成交量350,900股计算，目前短息比率为5.0天。

Wall Street Analyst Weigh In

华尔街分析师也加入进来

HCM has been the topic of a number of recent research reports. StockNews.com upgraded shares of HUTCHMED from a "sell" rating to a "hold" rating in a research note on Monday, August 1st. The Goldman Sachs Group boosted their price objective on HUTCHMED from $14.00 to $16.00 and gave the stock a "neutral" rating in a research report on Tuesday, August 9th.

HCM一直是最近一些研究报告的主题。在8月1日星期一的一份研究报告中，斯托克新闻网将和黄医药的股票评级从卖出上调为持有。8月9日，在周二的一份研究报告中，高盛夫妇将和黄医药的目标价从14.00美元上调至16.00美元，并给予该股“中性”评级。

Get
到达
HUTCHMED
和黄医药
alerts:
警报：

HUTCHMED Stock Performance

和黄医药股票表现

HCM traded up $0.23 on Friday, reaching $8.86. The company's stock had a trading volume of 444,340 shares, compared to its average volume of 449,485. The stock has a 50 day moving average of $12.27 and a two-hundred day moving average of $13.25. HUTCHMED has a fifty-two week low of $8.37 and a fifty-two week high of $36.81.

上周五，HCM股价上涨0.23美元，达到8.86美元。该公司股票的成交量为444,340股，而其平均成交量为449,485股。该股的50日移动均线切入位为12.27美元，200日移动均线切入位为13.25美元。和黄医药目前的52周低点为8.37美元，52周高点为36.81美元。

Institutional Investors Weigh In On HUTCHMED

机构投资者看好和黄医药

Several large investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of HUTCHMED by 5.6% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,767 shares of the company's stock valued at $317,000 after acquiring an additional 892 shares during the period. Cubist Systematic Strategies LLC raised its stake in shares of HUTCHMED by 4.5% during the second quarter. Cubist Systematic Strategies LLC now owns 22,273 shares of the company's stock worth $282,000 after purchasing an additional 950 shares during the last quarter. Citigroup Inc. raised its stake in shares of HUTCHMED by 4.6% during the fourth quarter. Citigroup Inc. now owns 35,237 shares of the company's stock worth $1,236,000 after purchasing an additional 1,565 shares during the last quarter. Baillie Gifford & Co. raised its stake in shares of HUTCHMED by 0.5% during the first quarter. Baillie Gifford & Co. now owns 365,792 shares of the company's stock worth $6,921,000 after purchasing an additional 1,724 shares during the last quarter. Finally, Asset Management One Co. Ltd. raised its stake in shares of HUTCHMED by 10.9% during the second quarter. Asset Management One Co. Ltd. now owns 17,519 shares of the company's stock worth $221,000 after purchasing an additional 1,724 shares during the last quarter. 27.37% of the stock is owned by institutional investors and hedge funds.
几家大型投资者最近调整了对该公司的持股。苏黎世广东银行在第一季度增持了5.6%的和黄医药股票。Zurcher Kantonalbank苏黎世广东银行在此期间额外收购了892股，现在拥有16,767股该公司股票，价值317,000美元。立体主义系统战略有限责任公司在第二季度增持了和黄医药4.5%的股份。Cubist Systems Strategy LLC在上个季度额外购买了950股后，现在拥有22,273股该公司股票，价值28.2万美元。去年第四季度，花旗集团将和黄医药的持股比例提高了4.6%。花旗集团(Citigroup Inc.)在上个季度增持了1,565股后，目前持有该公司35,237股，价值1,236,000美元。Baillie Gifford&Co.在第一季度增持了和黄医药的股份0.5%。Baillie Gifford&Co.现在持有365,792股该公司股票，价值6,921,000美元，在上个季度又购买了1,724股。最后，资产管理一号在第二季度增持了10.9%的和黄医药股份。Asset Management One Co.Ltd.在上个季度额外购买了1,724股后，目前持有该公司17,519股股票，价值221,000美元。27.37%的股票由机构投资者和对冲基金持有。

About HUTCHMED

关于和黄医药

(Get Rating)

(获取评级)

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.

和黄医药(中国)有限公司在香港和国际上发现、开发癌症和免疫疾病的靶向疗法和免疫疗法，并将其商业化。它在肿瘤学/免疫学和其他风险投资领域开展业务。该公司开发Savolitinib，一种治疗非小细胞肺癌(NSCLC)、乳头状细胞癌和肾癌、结直肠癌(CRC)和胃癌(GC)的抑制剂；以及Fruquintinib，一种治疗CRC、乳腺癌、GC、子宫内膜癌(EMC)、非小细胞肺癌、肝细胞癌以及胃肠道和实体肿瘤的抑制剂。

Further Reading

进一步阅读

  • Get a free copy of the StockNews.com research report on HUTCHMED (HCM)
  • EV Battery Maker Freyr Set For Major Global Expansion
  • MarketBeat: Week in Review 9/26 – 9/30
  • This Is A Memorable Time To Buy Into Micron Technology
  • Declining Profits Challenge the CarMax Value Proposition
  • Let Paychex Stock Work Hard For You
  • 免费获取斯托克新闻网关于和黄医药的研究报告
  • 电动汽车电池制造商Freyr将在全球大举扩张
  • MarketBeat：回顾一周9/26-9/30
  • 这是买入美光科技的难忘时刻
  • 利润下降对CarMax价值主张的挑战
  • 让Paychex股票为您努力工作

Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.

接受《和黄医药日报》的新闻和评级-在下面输入您的电子邮件地址，即可通过MarketBeat.com的免费每日电子邮件时事通讯接收对和黄医药及相关公司的最新新闻和分析师评级的每日摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发